30 Day Trial


Founded in 1992, ORTHOWORLD® is the only provider of strategic intelligence in the world solely focused on the global orthopaedic market. Its singular mission is helping orthopaedic companies and individuals improve their performance.

Highly specialized product offerings such as ORTHOWORLD Membership, ORTHOFLASH®, market reports, BONEZONE® and OMTEC® empower industry participants to respond to challenges, maximize opportunities and more aggressively expand their orthopaedic businesses. We welcome the opportunity to assist you.


  • 1:45 p.m. Episurf Medical received FDA approval for its IDE application to commence a clinical study of the Episealer® knee device.
  • 2:30 p.m. WishBone Medical was granted a global, non-exclusive license for sale of a guided growth plating system to treat pediatric deformed limbs. Product launch is slated for 1Q19
  • OrthoPediatrics commenced full U.S. launch of the RESPONSE 4.5/5.0mm system for the treatment of complex scoliosis.
Read More

Articles of Interest All Articles

FDA Priorities: People, Simplicity and a Risk-Based Approach to Speed Time to Market

By utilizing a more straightforward methodology, FDA can free up and better use resources to focus on high-risk areas that have the biggest impact. "Simplicity requires that FDA remain limber," writes John Gagliardi. "For industry to be innovative, the federal government must be innovative as well."